30.00
price down icon13.27%   -4.59
after-market Handel nachbörslich: 30.00
loading
Schlusskurs vom Vortag:
$34.59
Offen:
$34.86
24-Stunden-Volumen:
42,373
Relative Volume:
0.85
Marktkapitalisierung:
$200.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-13.04
EPS:
-2.3
Netto-Cashflow:
$-6.82M
1W Leistung:
-25.61%
1M Leistung:
-5.36%
6M Leistung:
+550.76%
1J Leistung:
+4,599%
1-Tages-Spanne:
Value
$28.24
$34.86
1-Wochen-Bereich:
Value
$28.24
$42.00
52-Wochen-Spanne:
Value
$0.3438
$54.30

Monopar Therapeutics Inc Stock (MNPR) Company Profile

Name
Firmenname
Monopar Therapeutics Inc
Name
Telefon
(847) 388-0349
Name
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Name
Mitarbeiter
16
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
MNPR's Discussions on Twitter

Vergleichen Sie MNPR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MNPR
Monopar Therapeutics Inc
30.00 200.92M 0 -7.12M -6.82M -2.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 26.46B 3.81B -644.79M -669.77M -6.24

Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-19 Fortgesetzt Piper Sandler Overweight
2025-01-10 Eingeleitet Piper Sandler Overweight
2024-10-11 Eingeleitet Rodman & Renshaw Buy
2021-01-28 Eingeleitet ROTH Capital Buy

Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten

pulisher
02:52 AM

Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World

02:52 AM
pulisher
01:23 AM

HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World

01:23 AM
pulisher
Apr 03, 2025

What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Monopar Therapeutics (NASDAQ:MNPR) Receives “Buy” Rating from HC Wainwright - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Top 5 Small-cap Biotech Stocks of 2025 - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN

Apr 01, 2025
pulisher
Apr 01, 2025

Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Projections Justify Buy Rating - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Buy Rating for Monopar Therapeutics Inc: Strategic Advancements and Promising Financial Outlook - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Monopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last year - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Monopar Therapeutics sees cash runway through December 31, 2026 - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

Monopar Therapeutics SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Monopar Secures 2-Year Runway with $60M War Chest, Advances Wilson Disease Drug - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView

Mar 27, 2025
pulisher
Mar 21, 2025

Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Monopar a new overweight at Piper Sandler on rare disease asset - Seeking Alpha

Mar 19, 2025
pulisher
Mar 19, 2025

Piper Sandler sets Monopar stock at $76 with Overweight rating - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Buy Rating for Monopar Therapeutics Inc. Driven by Strategic Acquisition and ALXN1840 Potential - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Piper Sandler sets Monopar stock at $76 with Overweight rating By Investing.com - Investing.com UK

Mar 19, 2025
pulisher
Mar 16, 2025

(MNPR) Trading Report - news.stocktradersdaily.com

Mar 16, 2025
pulisher
Mar 08, 2025

Monopar Therapeutics Inc.'s (NASDAQ:MNPR) 19% loss last week hit both individual investors who own 33% as well as institutions - Simply Wall St

Mar 08, 2025
pulisher
Mar 04, 2025

Monopar Therapeutics: Strong Data, But There Are Risks (NASDAQ:MNPR) - Seeking Alpha

Mar 04, 2025
pulisher
Mar 03, 2025

Monopar Therapeutics appoints new CFO - Investing.com

Mar 03, 2025
pulisher
Mar 03, 2025

Monopar Therapeutics Appoints Quan Vu as New CFO - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Monopar Therapeutics Inc Says On Feb 28, CFO Karthik Radhakrishnan'S Employment Terminated - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Monopar Therapeutics appoints new CFO By Investing.com - Investing.com Australia

Mar 03, 2025
pulisher
Feb 24, 2025

Monopar Therapeutics appoints new board member - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Monopar Therapeutics appoints new board member By Investing.com - Investing.com UK

Feb 24, 2025
pulisher
Feb 24, 2025

Monopar Therapeutics Appoints Lavina Talukdar to Board - TipRanks

Feb 24, 2025
pulisher
Feb 23, 2025

Trend Tracker for (MNPR) - Stock Traders Daily

Feb 23, 2025
pulisher
Feb 19, 2025

Copper wired: Monopar to electrify Wilson disease? - BioWorld Online

Feb 19, 2025
pulisher
Feb 13, 2025

Q1 EPS Estimate for Monopar Therapeutics Raised by Analyst - MarketBeat

Feb 13, 2025
pulisher
Feb 12, 2025

Learn to Evaluate (MNPR) using the Charts - Stock Traders Daily

Feb 12, 2025
pulisher
Feb 11, 2025

Brookline Capital Management Forecasts MNPR Q1 Earnings - Defense World

Feb 11, 2025
pulisher
Feb 06, 2025

Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - RTTNews

Feb 06, 2025
pulisher
Feb 04, 2025

Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - MSN

Feb 04, 2025
pulisher
Feb 03, 2025

Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Feb 03, 2025
pulisher
Jan 27, 2025

What's Going On With Cancer-Focused Monopar Therapeutics Stock Today? - MSN

Jan 27, 2025
pulisher
Jan 26, 2025

What is HC Wainwright’s Forecast for MNPR FY2026 Earnings? - Defense World

Jan 26, 2025
pulisher
Jan 24, 2025

Analysts Set Expectations for MNPR FY2029 Earnings - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

What is HC Wainwright's Forecast for MNPR FY2026 Earnings? - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Monopar Therapeutics Stock Hits 52-Week High at $38.91 By Investing.com - Investing.com South Africa

Jan 24, 2025
pulisher
Jan 23, 2025

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics - PR Newswire

Jan 23, 2025
pulisher
Jan 23, 2025

Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright - Yahoo Finance

Jan 23, 2025
pulisher
Jan 22, 2025

Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $40.00 - MarketBeat

Jan 22, 2025

Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Monopar Therapeutics Inc-Aktie (MNPR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Radhakrishnan Karthik
Chief Financial Officer
Oct 28 '24
Buy
16.25
1,550
25,188
1,550
Cittadine Andrew
Chief Operating Officer
Jun 20 '24
Buy
0.74
20,508
15,254
186,132
Cittadine Andrew
Chief Operating Officer
Jun 18 '24
Buy
0.86
12,000
10,320
165,624
Cittadine Andrew
Chief Operating Officer
Jun 14 '24
Buy
0.93
12,000
11,176
141,624
Cittadine Andrew
Chief Operating Officer
Jun 13 '24
Buy
0.91
12,000
10,920
129,624
Cittadine Andrew
Chief Operating Officer
Jun 17 '24
Buy
0.90
12,000
10,799
153,624
Cittadine Andrew
Chief Operating Officer
Jun 04 '24
Buy
0.78
12,000
9,360
117,624
Cittadine Andrew
Chief Operating Officer
Jun 03 '24
Buy
0.76
12,000
9,120
105,624
Cittadine Andrew
Chief Operating Officer
May 31 '24
Buy
0.64
12,000
7,732
93,624
Cittadine Andrew
Chief Operating Officer
May 30 '24
Buy
0.64
12,000
7,676
81,624
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):